Keyword: Esperion Therapeutics
Esperion's bempedoic acid is continuing its roll, lowering LDL cholesterol in patients with atherosclerosis.
Esperion’s phase 3 results of bempedoic acid showed it lowered cholesterol levels, but 13 deaths were also reported, causing shares to slide.
Esperion's bempedoic acid lowered LDL levels by 30% in patients on a PCSK9 blocker for cholesterol.
A 12-week course of Esperion's bempedoic acid lowered patients' LDL cholesterol by 23%.
The regimen lowered LDL cholesterol by 64%, a bigger drop than the combination of Zetia and Lipitor has achieved in other studies.